论文部分内容阅读
本实验对骨肉瘤患者外周血淋巴细胞(PBL)采用2种培养方法:(1)PBL在体外用患者肿瘤组织学相关传代骨肉瘤细胞(灭活处理)刺激5天再经rIL-2诱导12天;(2)单独rIL-2,激活培养PBL3～5天;分别获取rIL-2诱导体外刺激细胞毒淋巴细胞(rIL-2-CL)和LAK细胞。借助~(51)Cr释放试验对2种效应细胞形成及体外抗瘤能力进行比较性研究。结论:rIL-2-CL主要是一种特异性较高,杀伤活性强烈CTL细胞群,对抗LAK细胞的骨肉瘤细胞具有明显杀伤效应。
In this study, peripheral blood lymphocytes (PBL) from osteosarcoma patients were cultured in two ways: (1) PBL was stimulated in vitro with human tumor histologically related osteosarcoma cells (inactivated) for 5 days and then induced by rIL-2. (2) Activation of PBL for 3 to 5 days with rIL-2 alone; rIL-2-induced stimulation of cytotoxic lymphocytes (rIL-2-CL) and LAK cells in vitro. With the aid of ~(51)Cr release assay, two kinds of effector cell formation and in vitro antitumor ability were compared. Conclusion: rIL-2-CL is mainly a kind of CTL cell group with high specificity and strong killing activity. It has obvious killing effect against osteosarcoma cells of LAK cells.